| 000 | 01295cam a2200181 4500500 | ||
|---|---|---|---|
| 005 | 20250121081700.0 | ||
| 041 | _afre | ||
| 042 | _adc | ||
| 100 | 1 | 0 |
_aQuesada, Stanislas _eauthor |
| 700 | 1 | 0 |
_a Adenis, Antoine _eauthor |
| 700 | 1 | 0 |
_a Samalin, Emmanuelle _eauthor |
| 245 | 0 | 0 | _aHER2+ gastroesophageal adenocarcinomas: Current standards and therapeutic prospects |
| 260 | _c2022. | ||
| 500 | _a10 | ||
| 520 | _aEsogastric adenocarcinomas (EGAs) are characterized in 10–20% of cases by overexpression and/or amplification of HER2. Current standard treatment for HER2+ EGAs relies on trastuzumab (an anti-HER2 antibody) plus a doublet of chemotherapy (fluoropyrimidine + platinum salt). For more than a decade, no obvious therapeutic progress has enriched the therapeutic arsenal for these patients, whether in the first-line with other anti-HER2 agents or in the context of trastuzumab resistance. The first results of studies based on trastuzumab deruxtecan and immune checkpoint inhibitors are therefore likely to change management practices for HER2+ EGAs. | ||
| 786 | 0 | _nHépato-Gastro & Oncologie Digestive | 29 | 4 | 2022-04-01 | p. 507-513 | 2115-3310 | |
| 856 | 4 | 1 | _uhttps://shs.cairn.info/journal-hepato-gastro-oncologie-digestive-2022-4-page-507?lang=en&redirect-ssocas=7080 |
| 999 |
_c498630 _d498630 |
||